This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Tecentriq
  • /
  • A Study of Atezolizumab in Combination With Carbop...
Clinical trial

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Read time: 3 mins
Last updated:10th Jun 2015
Identifier: NCT02367794

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1021 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Actual Study Start Date: June 11, 2015
Estimated Primary Completion Date: August 1, 2018
Estimated Study Completion Date: February 15, 2023

- Experimental:
Arm A: Atezolizumab + Paclitaxel + Carboplatin
- Experimental: Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin
- Active Comparator: Arm C: Nab-Paclitaxel + Carboplatin

Category Value
Date last updated at source 2018-06-27
Study type(s) Interventional
Expected enrolment 1021
Study start date 2015-06-11
Estimated primary completion date 2018-08-01

View full details